



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2528131 A1 2004/12/16

(21) **2 528 131**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2004/06/03
(87) Date publication PCT/PCT Publication Date: 2004/12/16
(85) Entrée phase nationale/National Entry: 2005/12/02
(86) N° demande PCT/PCT Application No.: US 2004/017331
(87) N° publication PCT/PCT Publication No.: 2004/108840
(30) Priorités/Priorities: 2003/06/03 (10/453,410) US;
2003/12/23 (10/743,956) US; 2004/04/05 (10/818,158) US

(51) Cl.Int./Int.Cl. *C12N 15/11* (2006.01),
C12Q 1/68 (2006.01), *C12N 15/63* (2006.01),
C12N 5/10 (2006.01)

(71) Demandeur/Applicant:
CYTOGENIX, INC., US

(72) Inventeurs/Inventors:
CHEN, YIN, US;
TAN, XING XIN, US

(74) Agent: SMART & BIGGAR

(54) Titre : NUCLEOTIDES CONVENANT A LA PREVENTION ET AU TRAITEMENT DE PATHOLOGIES
BACTERIENNES ET FONGIQUES

(54) Title: NUCLEOTIDES FOR PREVENTION AND TREATMENT OF BACTERIAL AND FUNGAL PATHOLOGIES

(57) Abrégé/Abstract:
Published without an Abstract



NUCLEOTIDES FOR PREVENTION AND TREATMENT OF BACTERIAL AND FUNGAL PATHOLOGIES

Severe sepsis and septic shock are life threatening complications of infection and a common cause of death in intensive care units (Angus, *et al.*, 2001, Crit. Care Med., 29: 1303-1310). Recent surveys estimate that severe sepsis accounts for 2-11% of all admissions to hospital or intensive care units (Martin, *et al.*, 2003, New Engl. J. Med., 348, 1546-1554) and the incidence is rising due to the aging of the population and increasing numbers of immunocompromised and critically ill patients. Sepsis comprises a complex clinical syndrome resulting from infection by bacterial and/or fungal pathogens (Cohen, 2002, Nature, 420, 885-891). Normally, an immunologic cascade ensures a protective response to microorganism challenge. However, a deficient defense may allow infection to become established or harm the host through maladaptive release of endogenous inflammatory compounds. This cascade of inflammation and coagulation fuels the progression of sepsis, resulting in hypoxia, ischemia, organ dysfunction, and ultimately death for a large number of patients. Additionally, diabetic individuals or others who suffer from lymphedema are at risk from opportunistic pathogens due to the growth potential afforded by the edematous medium or lack of circulation. Such infections may result in severe cellulitis or related sequelae that lead to sepsis.

Gram negative bacilli (mainly *Escherichia coli*, *Klebsiella* spp., and *Pseudomonas aeruginosa*) and Gram positive cocci (mainly staphylococci and streptococci) are common microbial pathogens isolated from patients with severe sepsis and septic shock. (Bochud, 2001, Intensive Care Med., 27 (Suppl 1): S33-S48). Fungi, mostly *Candida*, account for about 5% of all cases of severe sepsis, but the incidence of fungal infections is increasing.

Gram negative infections occur in the lung, abdomen, bloodstream, or urinary tract. Endotoxins, in the form of lipopolysaccharides (LPS), are an important component of the outer membrane of gram negative bacteria and have a pivotal role in inducing gram negative sepsis (Alexander, *et al.*, 2001, J. Endotoxin Res., 7:167-202). Gram positive bacteria are usually responsible for infections of skin, soft tissue, and intravascular devices, as well as primary bloodstream and respiratory infections. It is

generally thought that the distinct cell wall substances of gram-positive bacteria and fungi trigger a similar cascade of events as gram negative bacteria, although the structures involved are not generally as well studied as gram-negative endotoxin. Gram positive bacteria can cause sepsis by at least two mechanisms: by producing
5 exotoxins that act as superantigens and by components of their cell walls stimulating immune cells (Calandra, 2001, J. Chemother., 13: 173-180). Gram positive bacteria without exotoxins can also induce shock, probably by stimulating innate immune responses through similar mechanisms to those in gram negative sepsis.

Numerous adjunctive treatments (other than antibiotics and supportive care)
0 for severe sepsis and septic shock have been tested, including neutralization of microbial toxins and pro-inflammatory cytokines, non-specific anti-inflammatory and immunosuppressive drugs, and correction of abnormalities in coagulation. The results have been mixed (Vincent *et al.*, 2002, Clin. Infect. Dis., 34: 1084-1093), and it does not appear that any one treatment addresses all sepsis conditions and/or causative
5 agents.

While theoretical and experimental animal evidence exists supporting the use of large doses of corticosteroids in severe sepsis and septic shock, all randomized human studies found that corticosteroids do not prevent septic shock, reverse the shock state, or improve mortality. Lefering, *et al.*, 1995, Crit. Care Med., 23, 1294-1303; Cronin,
10 1995, Crit. Care Med., 23, 1430-1439. Coagulation abnormalities are common in patients with sepsis and microvascular thrombosis. Treatment with activated protein C reduces mortality from severe sepsis (Bernard, *et al.*, 2001, N. Engl. J. Med., 344: 699-709). So far as is known, it is the only drug to treat sepsis in the current market. However, treatment with this drug results in modest improvements in patient mortality
25 at the price of a slight increase in bleeding events (*Id.*).

Prophylactic administration of antibiotics is, therefore, the treatment of choice for sepsis in hospitals (Cunha, 1995, Med. Clin. North Am., 79, 551-558). Antibiotics must be broad spectrum and cover gram-positive, gram-negative, and anaerobic bacteria because all classes of these organisms produce identical clinical presentations.
30 Antibiotics must be administered parenterally in doses adequate to achieve bactericidal serum levels because clinical improvement correlates with the achievement of serum bactericidal levels rather than the number of antibiotics administered.

Unfortunately, many classes of antibiotics have become less effective as a result of antibiotic resistance by bacteria such as *S. aureus*, *S. pneumoniae* and *E. faecalis* (Nicolaou, *et al.*, 2001, Scientific American, p. 56-61). Methicillin-resistant *S. aureus* (MRSA), penicillin-resistant *S. pneumococcus* and vancomycin-resistant *E. faecalis* (VRE) are now difficult to treat effectively (Pfaller, *et al.*, 1998, Antimicrobial Agents and Chemotherapy, 42:1762-1770; Jones, *et al.*, 1999, Microbiol. Infect. Dis., 33:101-112). Also alarming is the emergence of multi-drug resistance pathogens (Swartz, 1994, Proc Natl. Acad. Sci. USA, 91:2420-2427; Baquero, 1997, J. Antimicrobial Chemotherapy, 39:1-6). Fungal pathogens resistant to antifungal agents have also been documented and their frequency will likely increase (Rex, 1997, Clin. Infect. Dis., 24:235-247).

The development of drug-resistant bacterial and fungal pathogens implicated in sepsis illustrates the need for a new approach to treatment of sepsis. On a broader scale, the emergence of drug-resistant pathogens illustrates the need for a new approach for the treatment of any pathological condition in which a bacterial or fungal agent is implicated. Infectious diseases such as tuberculosis, meningitis, and pneumonia, that would have been easily treated with antibiotics at one time, are no longer so readily thwarted.

The present invention therefore utilizes oligonucleotide-mediated intervention (OMI) technology to alter the activity of genes involved in such pathological conditions for therapeutic purposes. The ability to produce single strands of DNA (ssDNA) of any sequence and length in selected cells enables targeted alteration of gene expression at the genomic level using triplex-forming oligonucleotides (TFOs), at the messenger RNA (mRNA) level using antisense and DNA enzyme oligos, and at the protein level using ssDNA as aptamers (Chen, 2002, Expert Opin. Biol. Ther. 2(7) 735-740). Antisense, DNA enzyme, triplex, and aptamer technologies provide an efficient alternative to more difficult methods such as creating gene knockout in cells and organisms. Antisense oligonucleotides (ODNs) block gene expression by Watson-Crick base pairing between an ODN and its target mRNA (Crooke, 1999, Biochim. Biophys. Acta 1489:31-44). Antisense ODNs have been used to effectively inhibit gene expression in eukaryotic cells and there is one antisense ODN-based product in the market and others in clinical trials (Uhlman, 2001, Expert Opinion Biol. Ther.,

1:319-328). However, antisense technology is not used extensively in prokaryotic systems. Prokaryotic cells have themselves developed endogenous antisense mechanisms for gene regulation (Simons, *et al.*, 1988, Ann. Rev. Genet., 22, 567-600). Earlier results indicated that gene expression in bacteria may be accessible to inhibition
5 by modified ODNs (Jayayaraman, *et al.*, 1981, PNAS, 78:1537-1541; Gasparro, *et al.*, 1991, Antisense Res Dev., 1:117-140). Others reported that peptide nucleic acid (PNA) can inhibit gene expression in bacteria (Good, *et al.*, 1998, Nature Biotechnology, 16:355-358). PNA, a DNA mimic in which the nucleotide bases are attached to a pseudopeptide backbone, hybridizes with complementary DNA, RNA, or
0 PNA oligomers through Watson-Crick base pairing and helix formation.

One major factor in the efficacy of any OMI strategy is target site accessibility. Base composition can affect heteroduplex formation, but it does not appear to be the primary factor. There is now evidence that binding of complementary ODNs is determined by the secondary and tertiary structure of RNA molecules (Frauendorf, *et al.*,
15 *et al.*, Bioorg. Med. Chem. Lett., 1996, 4:1019-1024). Various approaches to identifying the accessible sites on target mRNAs in relation to antisense and/or DNA enzyme design have been developed. Conventionally, a linear shot-gun approach in which several ODNs, targeted to various regions of an mRNA, are synthesized and their antisense, DNA enzymatic or other activity (or binding affinity to the target sites)
20 measured. However, only 2-5% of ODNs are generally found to be good antisense reagents. It is also known to use computer programs to select the target. For instance, the secondary structure of target RNA is predicted using an RNA folding program such as MFOLD (M. Zuker, 1989, Science, 244, 48-52) and antisense ODNs are designed to bind to regions that are predicted to be free from intramolecular base
25 pairing. However, energy-based prediction methods of RNA structure are largely inadequate for designing antisense reagents and success using this approach has been limited.

Evidence that ribonuclease H (RNase H) is involved in antisense-mediated effects has led to the development of procedures for identifying accessible mRNA
30 binding sites. In one procedure, RNase H is used with an ODN library comprising all possible ODNs of a defined length to identify accessible sites in mRNA. For instance, for a length N, there are N^4 different possible ODNs comprising the ODN library set

such that there are approximately 2.56×10^6 molecules for a 40-mer ODN. Library ODNs complementary to accessible sites on the target RNA produce hybrids with RNA that are identified as RNase H cleavage sites by gel electrophoresis and the library set members are tested to see which produces a down-regulating effect on a specific target mRNA. Controlled expression systems such as the tetracycline regulatory system in prokaryotic cells allow selective gene down- or up-regulation, thereby supplying information on the gene product.

Hammerhead and hairpin ribozymes are catalytic RNA molecules that bind and cleave defined RNA targets that have been used to knock down gene expression of viral and cellular targets (*see* James, *et al.*, Blood, 91:371-382, 1998). A method has been developed to identify accessible sites on ICP4 mRNAs for antisense-mediated gene inhibition using a hammerhead ribozyme library that allows expression of the library components in mammalian cells (Pierce, *et al.*, 1998, Nucleic Acid Research, 26:5093-5101). Although hammerhead ribozymes efficiently cleave specific mRNA targets, their clinical application is limited because of instability caused by RNase degradation *in vivo*. Ribozyme libraries can also be used to identify genes involved in producing a particular phenotype. Researchers from Immusol, Inc. constructed a hairpin ribozyme library that was delivered to mammalian cells with plasmid or retroviral vectors (Welch, *et al.*, Genomics, 66, 274-283, 2000, Li, *et al.*, Nucleic Acid Research, 28:2605-2612, 2000, Kruger, *et al.*, PNAS, 97:8566-8571, 2000, Beger, *et al.*, PNAS, 98:130-135, 2001). By knocking down gene expression, they were able to identify novel genes or new functions of known genes. However, similar to hammerhead ribozymes, hairpin ribozymes have limited stability *in vivo*.

Ji, *et al.* constructed a library of 200 to 800bp staphylococcal DNA fragments by shearing genomic DNA (Ji, *et al.*, 2001, Science, 293:2266-2269). By transforming the library into *S. aureus*, random antisense RNA molecules were generated. Using this approach, genes were identified that could serve as targets for antibiotic discovery. A similar approach was used by Forsyth, *et al.* in *S. aureus* (Forsyth, *et al.*, 2002, Molecular Microbiology, 43:1387-1400). However, this approach can only be used for the identification of essential genes since antisense RNA with the size between 200-800bp is not useful for therapeutic purposes because of 1) the instability of PNA

molecules; 2) the difficulty of synthesizing RNA molecules with the size of 200-800 bp; and 3) the problem of delivering RNA to appropriate cells.

There is, therefore, an emergent demand for the discovery and development of new therapeutics against bacterial and fungal pathogens. Recent advances in DNA sequencing technology have made it possible to elucidate the entire genome sequences of pathogenic bacteria. Genomic sequencing reveals all of the information in bacteria related to potential targets by antibiotics and therefore provides a more rational target-based approach to the development of new therapeutic agents. Thus, the use of a screening library to identify ODNs for inhibiting growth of bacteria and/or fungi, killing bacteria and/or fungi, or preventing bacteria and/or fungi from synthesizing and secreting toxins is one focus of the present invention. Use of the screening library to discover ODNs effective in eukaryotic (e.g., mammalian) cells for targeted alteration of gene function is a logical application.

It is, therefore, an object of the present invention to provide a method for identifying ssDNAs such as triplex forming oligos (TFOs), antisense oligos, DNA enzymes, or aptamers useful as therapeutic antibacterial and/or antifungal agents.

An additional object of the present invention is to provide a method for identifying bacterial and/or fungal genes that can serve as targets for discovery of antibacterial and/or antifungal agents.

An additional object of the present invention is the provision of a method, and ODNs, for treating bacterial and fungal infections.

An additional object of present invention is to provide a method for regulating gene expression in eukaryotic cells in a controlled manner using a selectively-inducible expression vector such as the tetracycline system.

Yet another object of the present invention is to identify genes necessary for bacterial and fungal viability and host genes associated with the exaggerated innate immune response indicative of sepsis.

An additional object of the present invention is to provide ODNs, and their sequences, that knock down (silence) bacterial, fungal, and host genes.

An additional object of the present invention is to provide ODNs, and their sequences, as therapeutic antibacterial and antifungal agents.

An additional object of the present invention is to provide means for delivery of therapeutic ODNs into target bacterial or fungal cells.

An additional object of the present invention is to provide plasmid constructions that are used to knock down bacterial, fungal, and host genes.

5 An additional object of the present invention is to provide plasmid constructions that are used as therapeutic antibacterial and antifungal agents.

Still another object of the present invention is to provide a treatment for a bacterial and/or fungal infection such as sepsis in an animal patient comprising the steps of contacting a bacterial or fungal causative agent with an ODN comprising a
10 sequence targeted to a specific gene of the causative agent for altering the expression of the specific gene to inhibit growth of the causative agent, kill the causative agent, or inhibit the synthesis or secretion of toxin by the causative agent.

These objects, and many others, are met by providing, a selectively-inducible single-stranded DNA (ssDNA) expression library, a method for constructing the
15 ssDNA expression library, a method for screening a ssDNA expression library, and a method for identifying ssDNA molecules that switch bacterial gene(s) related to cell growth, replication, and/or toxin production and secretion on or off. The method comprises a method for constructing a set of randomly ordered, fixed length oligodeoxynucleotide (ODN) strands and sub-cloning these ODNs into expression
20 vectors constituted so that, when transformed into cells that are subsequently exposed to certain chemical environments, the cell reacts by expressing the individual ODN sequence programmed into the expression vector. Cells containing instructions for an individual ODN are grown into colonies and each colony is divided into control and experimental sets. When an experimental colony is exposed to the chemical inducing
25 production of an ODN, the ODN is expressed and putatively alters cellular gene function, for instance, protein production, producing a different cell phenotype. If the phenotypic expression represents a desired end result, the control colony is treated to extract the DNA to determine the exact nucleotide sequence of the ODN that produced the phenotype in question.

30 This method is used to identify ODNs that inhibit the growth of, kill, or inhibit the synthesis or secretion of toxins by bacteria and/or fungi, thereby making it possible to identify new therapeutic agents against pathogenic bacteria and/or fungi and to

identify essential genes of the bacteria and/or fungus that can serve as additional targets for discovery of new therapeutic agents. The same methods and screening library are utilized to identify ssDNA molecules that switch bacterial and fungal gene(s) related to cell growth, replication, and/or toxin production and secretion on
5 and/or off.

The present invention comprises methods for treatment of bacterially- or fungally-induced diseases such as sepsis by producing ODNs in bacterial or fungal cells *in vivo* so that, when said ODNs reach and knock down their target genes, and thereby kill bacterial or fungal cells or inhibit their growth, the bacterial or fungal accumulation
10 in the bloodstream is held constant or diminished and the sepsis syndrome is reduced or eliminated.

In another aspect, the present invention provides a novel ssDNA enzyme having a catalytic sequence flanked by targeting sequences that are effective in killing bacterial or fungal cells into which the sequence is introduced and/or in which the
15 sequence is synthesized *in vivo*.

The present invention also comprises a method for treatment of sepsis in which ODNs are produced in host cells *in vivo* so that, when the ODNs silence their target genes, the host exaggerated innate immune response is abrogated and the sepsis syndrome is relieved.

20 The present invention also comprises a method for treatment of sepsis by delivering ODN-expressing plasmid constructions into host cells *in vivo* so that, when the ODNs are produced intracellularly and knock down their target genes, the host exaggerated innate immune response is abrogated and the sepsis syndrome is relieved.

In another aspect, the present invention also comprises a kit including an
25 oligonucleotide targeted to a gene in a microbial pathogen such as bacteria or fungi that operates to downregulate or otherwise alter the expression of the gene to kill the bacterial or fungal cells or inhibit their growth, or to decrease the synthesis or secretion of a toxin by the bacterial or fungal cell and a pharmaceutically acceptable excipient for use in treating a bacterial or fungal pathological condition.

30 Referring now to the figures, Figure 1 is a schematic representation of the plasmid pssXG constructed in accordance with the present invention and showing the content and organization of the biochemical instructions, in this instance, in the form of

a loop of double-stranded DNA that is introduced into a target bacterial cell, to cause the target cell to produce certain desired nucleic acids as described *infra*.

Figure 2 shows the plasmid pssXG of Fig. 1 as modified to produce an FtsZ gene-targeted DNA enzyme in a target cell, and designated pssXGb(FtsZ-DZ).

5 A critical component of the plasmid pssXGb(FtsZ-DZ) shown in Fig. 2 is the reverse transcriptase enzyme, and Figure 3 shows the results of a western blot assay for expression of HIS-tagged reverse transcriptase (RT) induced by tetracycline in *E. coli*. Bacterial cells carrying pssXGb(FtsZ-DZ) vector were grown at 37° C in the presence of 0, 100, or 200 ng/ml aTc for 1 hour (lanes 1-3), 2 hours (lanes 4-6), or 3
10 hours (lanes 7-9). Cell lysates were used for the assay and the RT bands are marked with an arrow, confirming the activity of the RT enzyme.

Figure 4 shows the results of a second assay for verifying the expression and activity of the reverse transcriptase (RT) in the pssXGb(FtsZ-DZ) plasmid shown in Fig. 2. In this assay, production of HIS-tagged RT in *E. coli* was induced by
15 tetracycline. Bacterial cells carrying vector were grown at 37° C until OD 280 value of 0.5 and then 200 ng/ml of aTc, a derivative of tetracycline, was added to the cells and incubated for another 1 – 2 hours. Cell lysates were used for the assay, conducted in accordance with Silver, *et al.* (1993, Nucleic Acids Res. 21: 3593-3594). Lane 1:
20 without tetracycline induction; Lane 2: one hour aTc induction; Lane 3: two hour aTc induction. PCR amplification product is marked by an arrow.

Figure 5A shows the predicted structure of the mRNA produced by the FtsZ gene (Tetart, *et al.*, 1992, Mol. Microbiol. 6: 615-620). The arrow indicates a loop at which the nucleic acids do not match up, thereby creating an opportunity for a single-stranded nucleic acid sequence to bind to the mRNA. As set out below, the GU site at
25 position 880 indicated by the arrow was exploited in designing an FtsZ mRNA-cleaving DNA enzyme. Figure 5B shows the design of this FtsZ mRNA-cleaving DNA enzyme (the 3' to 5' sequence) and its targeting sequence, or substrate (the 5' to 3' sequence), respectively.

Figure 6 shows the results of *in vitro* cleavage of FtsZ RNA and verifies that
30 the DNA enzyme of the present invention functions to digest the target mRNA. Lane 1 is a control reaction incubated for 2 hrs in the absence of DNA enzyme. S: substrate; P1 (857nt) and P2 (368nt): DNA enzyme digestion products.

Figure 7 shows the results of an assay using an antibody specific for FtsZ protein for detection of that protein in cells in which the pssXG and pssXGb(FtsZ) plasmids have been introduced when induced for the purpose of demonstrating DNA enzyme-mediated repression of *ftsZ* gene expression: A. bacterial cells carrying the pssXGb(FtsZ-DZ) vector; B. bacterial cells carrying the control pssXGa vector. As set out below, an inducible system was utilized to facilitate screening.

Figure 8A shows the inhibition of cell proliferation by the *in vivo* expressed FtsZ mRNA-cleaving DNA enzyme of the present invention.

Figure 8B shows the morphology of bacterial cells carrying pssXGb(FtsZ-DZ): A. bacterial cells carrying pssXGb(FtsZ-DZ), without aTc; B. bacterial cells carrying pssXGb(FtsZ-DZ), with 800 ng/ml aTc; C. bacterial cells carrying vector pssXGa, without aTc; and D. bacterial cells carrying pssXGa, with 800 ng/ml. The long filamentous cell (B) is indicative of a cell that cannot divide.

Figure 9 shows the result of library screening. Colonies were grown in duplicate in LB plates with or without aTc. Positive clone (containing the pssXGb vector including the sequence CYGX080103) is marked by an arrow.

Figure 10 shows the re-confirmation the inhibitory effect of the positive clone (CYGX080103, Fig. 9) from library screening. The CYGX080103 plasmid and the plasmid without ODN insert as negative control were transformed into DH5 α Pro and plated onto LB media with or without 200 ng/ml aTc. Fig. 10A shows that DH5 α Pro carrying the CYGX080103 plasmid grows normally on media without aTc, but not on media with aTc. DH5 α Pro carrying plasmid without the ODN insert grows on both media (Fig. 10B).

Figure 11 shows the results of transformation of ODN (CYGX080103) expression vector into *E. coli* XL10-gold (kan) cells. The transformants were plated on LB media with chloramphenicol and incubated at 37° C O/N. No XL10-gold(kan) cells carrying CYGX080103 expression plasmid grew on the LB media but the XL10-gold(kan) cells carrying the plasmid without the ODN insert grew normally.

Figure 12 shows survival of infected mice with or without ODN treatment. The log-phase preparation of bacteria was diluted in PBS, and 3X10⁸ CFU of bacteria was i.p. injected to induce mouse sepsis. To treat mice, the ODN was either mixed with bacteria *in vitro* and then injected or mice were pretreated by ODN before

infection. Serum was gathered and proinflammatory cytokines (IL-6, TNF, IL-1) and bacterial load tested and mouse behavior monitored at various time points after injection.

Figure 13 shows changes in mouse proinflammatory cytokine IL-6 4 and 24 hr after bacterial infection; IL-6 concentration was measured using a commercial kit.

Figure 14 shows bacterial growth inhibition by ODN. Immediately after diluting the O/N cultures 1/50, ODN was added to final concentrations of 4 μ M, 40 μ M or 400 μ M, with equal volume water as a negative control, and incubated with shaking at 30° C. After 2, 4 or 6 h, the growth was measured by viable cell count, which was done by diluting the cultures and plating on LB plates with streptomycin.

Figure 15 shows bacterial growth inhibition in competent Σ 10-gold(kan) cells transformed with ODN expression plasmid AS830103 or the plasmid without ODN insert plated onto LB media with chloramphenicol and incubated at 37° C O/N.

Figure 16 shows dose-dependent inhibition of bacterial growth by a peptide-PNA conjugate. As shown, the conjugate inhibited K-12 cell growth by 82-99.8%.

The methods and constructs of the present invention are better understood by reference to the following description of several embodiments thereof.

Construction of tetracycline-inducible prokaryotic ssDNA expression vector.

PCR amplification was carried out using the eukaryotic plasmid pssXE, described in International Application No. PCT/US00/27381, which application is hereby incorporated into this specification in its entirety by this specific reference, as the template. DNA primers used in the PCR reaction, 5'NheIPvuIATG

5'-CTAGCTAGCTAGCGATCGATGGGACCAATGGGGCAG-3' [Seq. ID No. 1]
and 3'KpnI

5'-CGGGGTACCAGTATTCCCTGGTC-3' [Seq. ID No. 2]

were synthesized by Integrated DNA Technologies (Coralville, IA). The PCR amplified DNA fragment was double-digested with NheI and KpnI and then subcloned into the pssXE vector that was double-digested with the same enzymes. The replacement removes the sequence before the translation starting site (ATG), which is unnecessary for prokaryotic gene expression, while creating a new restriction enzyme site, PvuI. The newly created construct was digested with PvuI and XbaI. The PvuI-

XbaI fragment contains all the essential elements for ssDNA production, including:

1) Mouse Moloney leukemia viral reverse transcriptase (MoMuLV RT) gene coding for a truncated but fully active RT (Tanase, *et al.*, PNAS, 2000, 85:1777-1781);

2) primer binding site (PBS) along with some flanking regions of the promoter that are

essential for the reverse transcription initiation by MoMuLV RT (Shinnick, *et al.*, Nature, 1981, 293:543-548); and 3) stem-loop structure designed for the termination

of the reverse transcription reaction all as described in the above-incorporated

International Application No. PCT/US00/27381. This DNA fragment was subcloned

into the pPROTet.E 233 vector (BD Bioscience, Palo Alto, CA) and the newly created

construct was designated as pssXGa, shown in Fig. 1. However, the sequence of

bacteria tRNA^{Pro} is different from mammalian tRNA^{Pro}, which was designed to bind

with the PBS in mammalian cells. Because bacterial tRNA^{Val} can be utilized as

primer for RT, a new PBS was designed to replace the PBS used in the vector pssXE

that is used for mammalian cells. The sequence of the novel PBS is

5'-TGGTGCGTCCGAG-3' [Seq. ID No. 3].

To construct a vector expressing the desired DNA enzyme and replace the original primer binding site (PBS) in the expression cassette of pssXE(CMV), the ODNs of sequence

5'-dTAACTGGATGATCGTTGTAGCTAGCCTTCGAAACTTGGTGGT-

GCGTCCGAGTGGACCGGGAGACCCCTGCTCGAGT-3' [Seq. ID No. 4]

and

5'-CTAGACTCGAGCAGGGGTCTCCCGGTCCACTCGGACGCACCACCAA-

GTTTCGAAGGCTAGCTACAACGATCATCCAGTTAAT-3' [Seq. ID No. 5]

were annealed to produce a synthetic duplex with 5'PacI and 3'XbaI cohesive ends and

ligated into the PacI and XbaI sites of pssXGa. The resulting vector was designated pssXGb(FtsZ-DZ) and is shown in Fig. 2.

pPROTet.E233 is a tetracycline-inducible bacterial expression vector expressing fusion protein with 6xHN. It utilizes the P_{Ltet}O1 promotor, which is tightly repressed by the highly specific Tet repressor protein and induced in response to anhydrotetracycline (aTc), allowing control of induction over a wide range (anhydrotetracycline is a derivative of tetracycline that acts as a potent inducer of PROTet.E Systems). The pssXG vector was transformed into the bacterial strain

DH5 α Pro (BD Bioscience, Palo Alto, CA) in the presence of 34 μ g/ml chloramphenicol (Cm) and 50 μ g/ml spectinomycin (spec). Spectinomycin is used to select for DH5 α Pro cells that carry transcription units encoding TetR (Lutz, *et al.*, Nucleic Acids Res., 1997, 25:1203-1210) The DH5 α Pro cells express defined amounts
5 of the Tet repressors. Cell lysates were prepared using B-PER II Bacterial Protein Extraction Reagent (Pierce, Rockford, IL) according to manufacturer's instruction. Using cell lysates, expression of reverse transcriptase (RT) was confirmed by RT activity assay using cell lysates according to Silver, *et al.* (Nucleic Acids Res., 1993, 21:3593-3594) as shown in Fig. 3 and with western blot using antibody against 6xHN
10 (BD Bioscience, Palo Alto, CA) as shown in Fig. 4.

Inhibition of Bacterial Growth By DNA Enzyme Targeted To FtsZ

Cell division is critical for bacterial survival; bacteria such as *E. coli* normally divide by binary fission, producing two daughter cells of equal size, each containing a nucleoid. FtsZ is an essential gene for bacterial division and viability. Division starts
15 with localization of FtsZ to the center of the mother cell and formation of a septal structure, the Z ring, and other essential cell division proteins are then recruited to the Z ring. Deletion and mutation of the FtsZ gene blocks cell division at an early stage and therefore presents a target of opportunity for a new therapeutic agent against a broad range of bacterial pathogens.

20 Because of their ability to bind and cleave any target RNA at purine/pyrimidine junctions, DNA enzymes are capable of interfering with gene expression as described in the above-incorporated International Application No. PCT/US00/27381. Based on the predicted secondary structure of FtsZ mRNA, DNA enzymes (DNAzymes) were designed for targeting various sites on this mRNA including, for instance, the loops at
25 positions 50-66, 530-547, 612-629, 648-662, 871-887, 958-972, and 1032-1048. Specifically, 10-23 DNA enzyme cleavage sites are plentiful in most biological substrates and thus provide the opportunity to achieve maximum cleavage efficiency, and a 10-23 DNA enzyme targeted against the GU site at position 880 was designed with the following 31 nt sequence:

30 5'-GTTTCGAAGGCTAGCTACAACGATCATCCAG-3' [Seq. ID No. 6]

with a predicted free energy 21.3 kcal/mol (Fig. 5). It will be apparent from Fig. 5 that this 31 nt enzyme is comprised of a 15 nucleotide catalytic domain flanked by random target-binding domains of eight nucleotides, but those skilled in the art who have the benefit of this disclosure will recognize that the target-binding domains may vary in size from as few as three nucleotides up to as many as 25 or more nucleotides. In a preferred embodiment, the target-binding domains are comprised of seven to ten nucleotides such that the enzyme takes the form

5'-N₁-GGCTAGCTACAACGA-N₂-3' [Seq. ID No. 7]

where N₁ and N₂ represent any sequence of nucleotides that target a specific RNA ranging in size from 3 to 25 nucleotides, and preferably seven to ten nucleotides.

The ability of the pssXGb(FtsZ-DZ) expression vector of the present invention to produce DNA enzyme molecules in bacterial cells was tested by evaluating the cleavage activity of the designed DNA enzyme in a cell-free system. The 1225 nt FtsZ RNA, produced by *in vitro* transcription, is used as a substrate and the cleavage assay is carried out at 37° C for various period of time as indicated in a 10 µl reaction containing 10 mM MgCl₂, 50 mM Tris-HCl, pH 7.5, 100 nM template FtsZ RNA, 100 µM DNA enzyme, and 10 units RNasin. As shown in Fig. 6, the synthetic DNA enzyme can effectively cleave the FtsZ RNA in as short a time as 0.5 hr, producing the products with expected sizes (368nt and 857nt).

Other DNA enzymes have been designed to target the loops of the FtsZ mRNA other than at position 880 as listed above. For instance, a DNAzyme was designed for targeting the loop at position 1032-1038 with the following sequence:

5'- CCTGCTTAGGCTAGCTACAACGATGGTCACC-3' [Seq. ID No. 8].

Given that the designed DNA enzyme has been shown capable of cleaving FtsZ RNA *in vitro* (Fig. 6) and an aTc regulated expression vector can produce active RT (Fig. 3 and 4), the expression vector is used to generate the DNA enzyme in cells and the effects of the DNA enzyme on the expression of the FtsZ gene is then determined. As shown in Fig. 7, bacterial cells carrying the pssXGb(FtsZ-DZ) vector (A) as well as negative control cells carrying the pssXGa vector (B) may be grown in the presence of various amount of aTc (0, 200, 400, 800 ng/ml) for 3 hrs. Compared to the cells grown in the absence of aTc, the FtsZ expression level in the bacterial cells carrying

pssXGb(FtsZ-DZ) is reduced significantly upon addition of aTc (Fig.7A). This reduction is not observed in the control cells (Fig.7B).

Because FtsZ gene is essential for bacterial division and viability and Fig. 7 indicates that the intracellularly-generated DNA enzyme significantly represses FtsZ expression, the effect of the expressed DNA on bacterial cell proliferation was investigated. Bacterial cells carrying the pssXGb(FtsZ-DZ) vector were grown in the presence of various amounts of aTc (0, 200, 400, 800 ng/ml) for either 1 or 2 hrs and viable cells were enumerated. As shown in Fig. 8A, cell growth was inhibited in time and aTc-concentration dependent manner. Furthermore, long filamentous cells were observed to be formed as a result of the cell growth inhibition (Fig. 8B).

Construction of a tetracycline-inducible ssDNA or ODN expression library.

Library inserts were generated by annealing three ODNs, CY(SacII)-40,
CTCTCACTCC(N)40ACTGTTGAAAGGC [Seq. ID No. 9]

CY(SacII)-L,
CGGAGAGTGAGG [Seq. ID No. 10]

and CY(SacII)-R,
CTTTCAACAGT [Seq. ID No. 11]

at the molar ratio of 1:20:20. "N" represents any base A, T, C, or G. There are thus 40-mer sequences randomly synthesized and represented as CY(SacII)-40 ODNs. The ODNs were mixed and denatured at 95°C for 3 min and then cooled slowly to room temperature over approximately 1 hr. Since CY(SacII)-L complements the left arm of CY(SacII)-40, while CY(SacII)-R complements the right arm of the same ODN, partial double-stranded ODNs are formed by the annealing process. The annealed ODN formed a partial double-stranded DNA and was filled in those remaining single-stranded Ns and blunt ended using the DNA Polymerase I, Large (Klenow) Fragment (New England Biolabs, Beverly, MA). The double-stranded DNA was then subcloned into the prokaryotic ssDNA expression vector pssXGb and transformed into DH5αPRO cells by electroporation.

DNA enzyme expression library is constructed similarly using a. DZlib1

5'-CTCGAGTCTAGANNNNNNNNGGCTAGCTACAACGANNNNNNNN-
NTTAATTAAGCTAGC-3' [Seq. ID No. 12]

(N can be either A or T, or C or G) and b. DZlib2

5'-GCTAGCTTAATTAA-3'

[Seq. ID No. 13].

The two oligonucleotides are mixed at a molar ratio of 1:20(a:b) and annealed to form a partial double-stranded DNA by heating for 5 min at 75° C, then cooled slowly to room temperature. The recessed 3' termini of the partial double-stranded DNA was filled by Klenow fragment, and the resulting double-stranded DNA digested with PacI and XbaI. The double digested products were then gel purified. After phenol extraction and ethanol precipitation, the PacI/XbaI digested library DNA was cloned into the pssXGb expression vector.

10 ssDNA expression library screening.

Since the ssDNA expression library was constructed based on a tetracycline inducible vector, bacterial cells containing the ssDNA expression library were plated in duplicate in Luria broth (LB) plates in the presence or absence 200 ng/ml aTc. Colonies growing only in the absence of aTc, as shown in Fig. 9, were identified as positive colonies. Plasmid DNA was extracted from the positive colony from the library screening, and the insert sequences determined by 3' end single-pass sequencing. The insert generated by this set of experiments was named CYGX080103, with sequence of:

20 5'-CTTTCAACAGTTTGTGACCTTTGCTGACCATAACAATTGC-
GATATCGTGGGGAGTGAGAG-3'

[Seq. ID No. 14].

The sequence was then analyzed using GenBank BLASTN program to identify the potential gene targets based on sequence homologies. The ODNs comprised in the CYGX080103 and their potential genes that can be knocked down in accordance with the present invention include, but are not limited to, CYGX08010301

25 5'-CCTTTGCTGACCATAC-3'

[Seq. ID No. 15]

and its target btuE (GenBank ID: NP-416225.1), CYGX08010302

5'-GACCTTTGCTGACCA-3'

[Seq. ID No. 16]

and its target CaiB (GenBank ID: NP-414580.1), CYGX08010303

30 5'-ACAGTTTGTGATGAC-3'

[Seq. ID No. 17]

and its target ydgD (GenBank ID: NP-418152.1), CYGX08010304

- 5'-ACAATTGCGATAT-3' [Seq. ID No. 18]
and its target ygcQ (GenBank ID: NP-417249.2), CYGX08010305
- 5 5'-GACCTTTGCTGAC-3' [Seq. ID No. 19]
and its target ftsH (GenBank ID: NP-417645.1), CYGX08010306
- 5'-TCAACAGTTTTTGATGAC-3' [Seq. ID No. 20]
and its target ppiB (GenBank ID: NP-415058.1), CYGX08010307
- 10 5'-ATGACCTTTGCTG-3' [Seq. ID No. 21]
and its target yihI (GenBank ID: NP-418308.1), CYGX08010308
- 5'-CAGTTTTTGATGA-3' [Seq. ID No. 22]
and its target zntA (GenBank ID: NP-417926.1), CYGX08010309
- 15 5'-ACCTTTGCTGAC-3' [Seq. ID No. 23]
and its target yicI (GenBank ID: NP-418116.1), CYGX08010310
- 20 5'-TTGCTGACCATA-3' [Seq. ID No. 24]
and its target fhuA (GenBank ID: NP-414692.1), CYGX08010311
- 5'-TGACCTTTGCTG-3' [Seq. ID No. 25]
and its target rplD (GenBank ID: NP-417778.1), CYGX08010312
- 25 5'-GTTTTGATGACC-3' [Seq. ID No. 26]
and its target ilvB (GenBank ID: NP-418127.1), CYGX08010313
- 5'-GCGATATCGTGG-3' [Seq. ID No. 27]
and its target lepB (GenBank ID: NP-417063.1), CYGX08010314
- 30 5'-TTGATGACCTTT-3' [Seq. ID No. 28]
and its target aroK (GenBank ID: NP-417849.1), CYGX08010315
- 35 5'-TGGGGAGTGAG-3' [Seq. ID No. 29]
and its target mfd (GenBank ID: NP-415632.1), CYGX08010316
- 5'-TTGCTGACCAT-3' [Seq. ID No. 30]
and its target rlpA (GenBank ID: NP-415166.1), CYGX08010317
- 40 5'-TTTTGATGACC-3' [Seq. ID No. 31]
and its target accA (GenBank ID: NP-414727.1), CYGX08010318

5'-TGATGACCTTT-3'

[Seq. ID No. 32]

and its target *pgpA* (GenBank ID: NP-414952.1).

The antibacterial efficacy of the ODN CYGX080103 was further evaluated in two separate experiments. The first was designed to examine the conditionally lethal effect of the ODN expression plasmid in the host cell DH5 α Pro, the bacterial strain employed in the library screening. The second experiment was designed to study the effect of the ODN expression plasmid on other bacterial strains. In the first study, the ODN expression plasmid and the plasmid without ODN insert as negative control were transformed into DH5 α Pro and plated onto LB media with or without 200 ng/ml aTc. As shown in Fig. 10A, DH5 α Pro cells carrying the ODN expression plasmid grow normally on the media without aTc but not on media with aTc. DH5 α Pro cells carrying the plasmid without the ODN insert grow on both media (Fig. 10B). In the second study, the ODN expression plasmid and the plasmid without ODN insert were transformed into *E. coli* XL10-gold(kan). The resulted transformants were plated on LB media with chloramphenicol, and incubated at 37° C O/N. As shown in Fig. 11, no XL10-gold(kan) carrying ODN expression plasmid grew on the LB media, while the XL10-gold(kan) carrying the plasmid without the ODN insert grew normally.

Development of a mouse sepsis model.

E. coli SM101, a temperature-sensitive UDP-N-acetylglucosamine acyltransferase mutant that loses all detectable acyltransferase activity, and its wild-type K12, were i.p. injected as described below to induce sepsis in mice. SM101 has a defect in lipid A biosynthesis that causes the outer membrane to be permeable to high-molecular-weight substances. The lipid A content of SM101 is reduced 2-3-fold compared with the wild-type. To prepare the bacteria for mouse infection, log-phase cultures of SM101 were grown in LB medium at 37° C to an optical density at 600 nm of 1.1 (equivalent to 5×10^8 CFU/ml), followed by centrifugation and resuspension in sterile phosphate-buffered saline (PBS) at 4° C. This log-phase preparation of bacteria was serially diluted in PBS, and 3×10^8 CFU of bacteria was i.p. injected to induce mouse sepsis. Serum was gathered and pro-inflammatory cytokines (IL-6, TNF, IL-1) and bacterial load tested, and mouse behavior monitored, at various time points after injection. All mice bled at every 24 hours. At 6 hours, mice showed evidence of

infection (lethargy, warm to the touch, scruffy). As shown in Fig. 12, around 60% mice died within 48 hours after infection. As shown in Fig. 13, 3 of 5 mice showed significant decrease in serum IL-6 concentration. The following table shows mouse bacterial load in blood after infection.

	Number of Mice Bled	CFU/ml
Control*	6	0, 0, 3.6×10^3 , 1.6×10^3 , 4.6×10^5 , $>10^5$
PNA [10 μ M]	4	0, 0, 0, 0
IP, PNA [100 μ M]	4	0, 0, 0, 0

* Septicemic mice succumbed to infection prior to 46 h.

Serum sample was collected at 24 hrs after infection for cell growth assay by measuring viable cell count. Viable cell count was done by diluting the cultures and plating on LB plates. Plates were incubated overnight at 37°C and the number of colonies enumerated by visual inspection.

Inhibition of bacterial growth by ODN.

The inhibition of bacterial growth by ODN was evaluated by examining the effect of ODN dosage on SM101 growth. In this study, an ODN having the sequence CTC ATA CTC T was added to the 1/50 diluted O/N SM101 cell cultures, at final concentration of 40 μ M or 400 μ M, with addition of equal volume water as a negative control, and incubated with shaking at 30° C. After 2, 4 or 6 h, the growth was measured by either the optical density at 600 nm (OD600) or viable cell count, which was done by diluting the cultures and plating them in triplicate on LB plates with streptomycin. As shown in Figure 14, upon addition of ODN, cell growth was inhibited by 86-96%.

Inhibition of bacterial growth by ODN expression plasmid.

In this study, the ODN expression plasmid As080103, having the sequence CYGX080103 listed above, and plasmid pssxGb without ODN insert as negative control, were transformed into E. coli XL10-gold(kan). The resulting cell cultures were plated on LB media with chloramphenicol and incubated at 37° C O/N. As shown in Figure 15, no XL10-gold(kan) carrying ODN expression plasmid grew on the LB media.

Establishing lethal dose (LD70) in the mouse model.

Six-week-old mice Balb/c (in groups of five) were used for infection experiments. A serial dilution of SM101 was injected intraperitoneally (i.p.) into mice in 400 µl aliquots. The animals were observed for 100 h. Mice inoculated with bacteria were scored for their state of health on a scale of 5 to 0 based on progressive disease states reflected by several clinical signs. A normal and unremarkable condition was scored as 5; slight illness, defined as lethargy and ruffled fur, was scored as 4; moderate illness, defined as severe lethargy, ruffled fur, and hunched back, was scored as 3; severe illness, with the above signs plus exudative accumulation around partially closed eyes, was scored as 2; a moribund state was scored as 1; and death was scored as 0. While experiments were not conducted in a double-blind manner all animals were evaluated by two or more independent observers. These experiments established that 10^9 CFU of strain SM101 is the LD70 for 6-week-old mice Balb/c, with ~60% mice that received the LD70 dose dying within 48 h. This LD70 was used in the DNA therapy experiments described *infra*. A similar approach was used to establish the LD70 for *E. coli* strain K-12.

Treatment of sepsis using ODN.

The efficacy of ODN therapy was evaluated in two experiments using the above-described SM101 bacteremia mouse model. The first examined the effect of DNA dose on the ability of ODN to rescue mice from SM101 bacteremia. The second studied the effect on the outcome of delaying treatment for various periods. In the dose-ranging study, five groups of mice (five mice in each) were challenged by i.p. injection of the LD70 of SM101. Each group was treated with a single injection of the ODN

CTC ATA CTC T [Seq. ID No. 33], administered i.p. immediately after the bacterial challenge at 4 nmol, 40 nmol, 400 nmol and 0 nmol. As an additional control, a fifth group (two mice) was not challenged with bacteria, receiving only the injection of ODN (at the highest dose). The state of the health of these animals was monitored for one week. Figure 12 shows survival of infected mice with or without ODN treatment.

Delivering plasmid to target bacterial cells by bacteriophage T3 extracts.

A standard DNA packaging reaction mixture (25 μ l) contains 0.5 mg plasmid DNA, 2×10^{10} phage equivalent(peg) of prohead, 20 pmol of gp 18 and 3 pmol of gp 19 in complete pac buffer. The reaction mixture was incubated at 30° C for 30 min for DNA packaging and the reaction was terminated by the addition of 1 μ l of 2 mg/ml of DNaseI. After incubation at 30° C for 20 min, the filled heads were converted to infectious particles by incubation with a head acceptor extract containing tail and tail fiber proteins. Proheads were prepared through a sucrose gradient centrifuge of lysates of bacterial cells infected with bacteriophage T3, as described by Nakasu, *et al.* (1983, Virology, 127, 124-133). gp 18 and gp 19 proteins were purified as described by Hamada, *et al.* (1986, Virology, 151, 110-118). The head acceptor extracts were isolated from lysates of bacterial cells infected by bacteriophage T3 and purified through ammonium sulfate precipitation. The resulting infectious particles contain the ODN expression plasmid for delivery to the target bacterial cells.

15 Inhibition of bacterial growth by peptide-ODN conjugate.

The inhibition of bacterial growth by peptide-PNA conjugate was evaluated by examining the effect of conjugate dose on the ability of conjugate to inhibit K12 growth. In this study, a peptide-ODN conjugate having the sequence

KFFKFFKFFK-CTC ATA CTC T

[Seq. ID No. 34]

was added to the 1/50 diluted O/N K12 cell cultures, and final concentration of 4 μ M, 40 μ M, or 400 μ M, with addition of equal volume water as a negative control, and incubated with shaking at 37° C. Immediately after diluting the O/N culture 1/50, peptide-ODN conjugate was added to final concentration of 4 μ M, 40 μ M, or 400 μ M, with addition of equal volume water as a negative control, and incubated with shaking at 37° C. After 2 hours, growth was measured by viable cell count by diluting the cultures and plating in triplicate on LB plates. As shown in Figure 16, upon addition of peptide-ODN conjugate, cell growth was inhibited by 82-99.8%.

Reduction of mouse bacterial load in blood by peptide-ODN conjugate.

The efficacy of peptide-ODN conjugate therapy was evaluated by examining the ability of the conjugate to reduce mouse bacterial load in blood. In this study, the log-phase preparation of K12 was diluted in PBS and six-week old mice Balb/c were

infected by i.p. injection of 3×10^9 CFU wild-type bacteria K12. The infected mice were treated with a single injection of 50 nmol peptide-ODN conjugate [Seq. ID No. 34], administered i.p. 30 min after the bacterial challenge. The conjugate was either mixed with bacteria *in vitro* and then injected in mice or mice were pre-treated by conjugate 30 min after infection. Serum samples were collected at 24 hrs after infection, for cell growth assay by measuring viable cell count. Viable cell count was done by diluting the cultures and plating them on LB plates. The results are shown in the following table:

	Number of Mice Bled	CFU/ml
Control*	3	1.3×10^6 , 1.4×10^5 , 1.3×10^5
PNA [10 μ M]	4	5.1×10^4 , 9.4×10^4 , 7.0×10^5 , 1.5×10^4
IP, PNA [100 μ M]	4	2.1×10^4 , 1.1×10^5 , 6.8×10^4 , 160

* * * * *

The present invention relates to a new strategy for combating bacterial and fungal pathogens, wherein selected ODNs and the expression plasmid used to produce them are used as therapeutic agents. One such pathogenic condition that is treated successfully utilizing the ODNs and expression plasmids of the present invention is sepsis. Examples of sepsis-causing microorganisms that can be treated in accordance with the present invention include, but are not limited to, those that cause infections in the lung, abdomen, bloodstream, skin, soft tissue, infections associated with intravascular devices, and respiratory infections. Examples of other pathogenic microorganisms that can be treated in accordance with the present invention include, but are not limited to, Gram-negative bacteria such as Bacteroides, Fusobacterium, Escherichia, Klebsiella, Salmonella, Shigella, Proteus, Pseudomonas, Vibrio, Legionella, Haemophilus, Bordetella, Brucella, Campylobacter, Neisseria, Branhamella; Gram-positive bacteria such as Streptococcus, Staphylococcus, Peptococcus, Bacillus, Listeria, Clostridium, Propionibacteria; organisms that stain poorly or not at all with Gram's stain such as Mycobacteria, Treponema, Leptospira, Borrelia, Mycoplasma, Chlamydia, Rickettsia and Coxiella; and fungi such as Candida, Aspergillosis, Blastomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Paracoccidiomycosis, Sporotrichosis, Zygomycosis.

Examples of bacterial target genes that can be knocked down in accordance with the present invention include, but are not limited to, those identified from library screening and those chosen based upon knowledge of bacterial physiology. A target gene can be found among those involved in one of the major process complexes: cell division, cell wall synthesis, protein synthesis (translation), nucleic acid synthesis, fatty acid metabolism, and gene regulation. Therefore, examples of bacterial target genes that can be knocked down in accordance with the present invention include, but are not limited to the above-described FtsZ gene, MurB, acpP, 16s rRNA, PBPs, DNAA, DNAC, pcrA, rpoB, rpoA, rpoC, rpsC, rpsD, rpsF, rpsI, rpsJ, rpsM, rpsR, FabK, FabH, rplB, rplC, rplJ, rplK, rplM, rplN, rplO, rplP, rplR, rplT, rplV, rplX, rpmA, rpmL, valS, serS, proS, cysS, alaS, pheS, sporC, tsf, tufA, fus, secA, secV, pyrC.

The target genes critical to fungal viability can be found among those involved in one of the major process complexes: cell division, cell wall synthesis, protein synthesis (translation), nucleic acid synthesis, fatty acid metabolism, and gene regulation. Therefore, examples of fungal target genes that can be knocked down in accordance with the present invention include, but are not limited to, ERG1, ERG2, ERG3, ERG4, ERG5, ERG6, ERG7, ERG11, ERG24, ERG25, ERGX, ERGY, CHS1, CHS2, CHS3, CWP1, CWP2, KRE1, KRE2, KRE5, KRE11, TIP1, GFA1.

ODN technology can down-regulate the over-expression of the host genes associated with the exaggerated innate immune response in sepsis, so that appropriate host response to an infection remains. Examples of host target genes that can be knocked down in accordance with the present invention include, but are not limited to, tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-12 (IL-12), interleukin-15 (IL15), nitric oxide synthase (NOS), high mobility group 1 protein (HMG-1), migration inhibitory factor (MIF), kinins, platelet-activating factor receptor antagonist (PAFra), soluble phospholipase A2 (sPLA2). In particular, TNF is considered to be one of the most important inflammatory mediators in the sepsis cascade. TNF is significantly elevated during sepsis (Casey, *et al.*, 1993, Ann. Intern. Med. 119:771-778; van der Poll, *et al.*, 1995, Shock, 1-12), and levels of TNF have been associated with severity of sepsis and clinical outcome (Calandra, *et al.*, 1990, J. Infect. Dis. 161:982-987; Cannon, *et al.*, 1990, J. Infect. Dis., 161:79-84). Moreover, most of the deleterious effects of sepsis can be mimicked by the administration of TNF

(Okusawa, *et al.*, 1988, J. Clin. Invest., 81:1162-1172; Natanson, *et al.*, 1989, J. Exp. Med., 169:823-832).

Examples of the ODN therapeutics that are used to treat sepsis in accordance with the present invention include, but are not limited to, CYGX080103, wherein, its
 5 sequence is 5'(CTT TCA ACA GTT TTG ATG ACC TTT GCT GAC CAT ACA ATT GCG ATA TCG TGG GGA GTG AGA G)3', and its potential targets are *btuE* (GenBank ID: NP_416225.1), *CaiB* (GenBank ID: NP_414580.1), *ydgD* (GenBank ID: NP_418152.1), *ygcQ* (GenBank ID: NP_417249.2), *ftsH* (GenBank ID: NP_417645.1), *ppiB* (GenBank ID: NP_415058.1), *yihI* (GenBank ID: NP_418308.1),
 10 *zntA* (GenBank ID: NP_417926.1), *yicI* (GenBank ID: NP_418116.1), *fhuA* (GenBank ID: NP_414692.1), *rplD* (GenBank ID: NP_417778.1), *ilvB* (GenBank ID: NP_418127.1), *lepB* (GenBank ID: NP_417063.1), *aroK* (GenBank ID: NP_417849.1), *mfd* (GenBank ID: NP_415632.1), *rlpA* (GenBank ID: NP_415166.1), *accA* (GenBank ID: NP_414727.1), *pgpA* (GenBank ID: NP_414952.1); CYGX_{acpP},
 15 wherein, its sequence is 5'(CTC ATA CTC T)3' in PNA form, and its target is the bacterial essential fatty acid biosynthesis gene *acpP* (GenBank ID: NP_309499); CYGX_{FtsZDZ}, wherein, its sequence is 5'(GTT TCG AAG GCT AGC TAC AAC GAT CAT CCA G)3', and its target is the bacterial essential cell division gene *FtsZ* (GenBank ID: NP_308126).

20 Examples of the DNA therapeutics that are used to treat sepsis in accordance with the present invention include, but are not limited to, regular ODN and its expression plasmid, its modification forms such as locked nucleic acids (LNA), peptide nucleic acids (PNA) such as those described above, phosphorothioates, or phosphorothioates morpholino oligomer (PMO).

25 Examples of means for delivering the ODNs and the said ODN expression plasmids of the present invention into bacterial or fungal cells for treatment of bacterial or fungal pathogenic conditions in accordance with the present invention include, but are not limited to, direct injection of naked DNA; cationic polymers such as PEI, EPEI, and porphyrins; viral vectors such as retroviruses and adenoviruses; cationic
 30 liposomes such as DOTAP and DOTMA; and peptides such as Xaa Xaa Xaa Lys Lys Arg Arg Xaa Xaa Xaa Xaa Xaa Xaa Thr Trp Xaa Glu Thr Trp Trp Xaa Xaa Xaa, Lys Xaa Xaa Trp Trp Glu Thr Trp Trp Xaa Xaa Ser Gln Pro Lys Lys Xaa Arg Lys Xaa,

Tyr Gly Phe Lys Lys Xaa Arg Arg Pro Trp Thr Trp Trp Glu Thr Trp Trp Thr Glu Xaa, wherein any Xaa can be any amino acid. The ODN expression plasmids of the present invention are also delivered into bacterial or fungal cells by packaging the plasmids into infectious particles using phage extracts as detailed above.

5 The anti-fungal sequences (AFS) and anti-bacterial sequences (ABS) of the present invention can be incorporated into plasmids, viral, and other vectors as known in the art and packaged in liposomes, cationic polymers such as PEI, or other excipient(s) and used, for instance, prophylactically to prevent or reduce the likelihood of infections such as the infections that lead to sepsis. Such uses include, but are not
10 limited to, sprayed applications on the skin or onto the site of surgical incisions to reduce bacterial loads and thus to reduce the risk of infection. The AFS and ABS of the present invention are also used to advantage in this same manner against local infections and by systemic infusion intravenously. A "cocktail" of AFS and ABS for
15 common microbial pathogens is administered for this purpose or, once the bacterial or fungal pathogen is cultured and identified, the appropriate sequence(s) for the specific pathogen are chosen and administered.

 The AFS and ABS of the present invention are also used in conjunction with sequences against a host's inflammation related proteins such as the Intercellular Adhesion Molecule (ICAM) in the manner described in International Application No.
20 PCT/US02/12345, assigned to the same Assignee of the present invention. Combined use of the anti-inflammatory and anti-bacterial sequences can reduce the risk of infection and scarring from surgical procedures. The combined sequences are also useful as a treatment for inflammatory conditions that lead to infections such as decubiti (bed sores).

25 Those skilled in the art who have the benefit of this disclosure will recognize that certain changes can be made to the component parts of the apparatus of the present invention without changing the manner in which those parts function to achieve their intended result. All such changes, and others that will be clear to those skilled in the art from this description of the invention, are intended to fall within the scope of
30 the following, non-limiting claims.

WHAT IS CLAIMED IS:

1. An oligodeoxynucleotide (ODN) library comprising a plurality of oligodeoxynucleotides of specific length, at least one of the oligodeoxynucleotides comprising said ODN library being capable of interacting with a target genomic DNA, mRNA or protein when inserted into a DNA expression vector with the specific calling sequence for said oligodeoxynucleotide being embedded in said expression vector, said expression vector being capable of being introduced into a target cell to produce at least one of said oligodeoxynucleotides when induced by exposure to a chemical agent for interacting with genomic DNA, mRNA or protein with observable result.

2. A process for identifying and isolating an oligodeoxynucleotide comprising the steps of:

utilizing the ODN library of claim 1 to express a plurality of copies of at least one said oligodeoxynucleotide in the target cell;

growing the target cells into a colony of cells;

dividing the colony into paired colonies;

exposing one of the paired colonies to a chemical agent capable of inducing expression of said at least one oligodeoxynucleotide by the cells of the exposed colony, causing the expressed oligodeoxynucleotide to interact with genomic DNA, mRNA or a protein to alter expression of a gene;

observing the result in said exposed cells; and

sequencing the DNA of the cells of the unexposed colony to identify the sequence of the library oligodeoxynucleotide that caused alteration of the gene.

3. The method of claim 2 wherein said cells are bacteria strain DH5 α Pro.

4. The plasmid pssXG.

5. The plasmid of claim 4 comprising a PBS having the sequence 5'-TG GTGCGTCCGAG-3' [Seq. ID No. 3].

6. A cell having the plasmid of claim 4 transformed therein.

7. A prokaryotic cell having the plasmid of claim 4 transformed therein.

8. The plasmid of claim 4 comprising a sequence coding for *in vivo* expression of a single-stranded DNA enzyme targeted to the mRNA transcript of the bacterial FtsZ gene.

9. The plasmid of claim 8 wherein the single-stranded DNA enzyme is specific for a GU site at position 880 of the bacterial FtsZ gene.

10. The plasmid of claim 8 wherein the single-stranded DNA enzyme comprises 5'-N₁-GGCTAGCTACAACGA-N₂-3' [Seq. ID No. 7] where N₁ and N₂ represent any sequence of nucleotides ranging in size from about seven to about ten nucleotides that target a specific RNA.

11. A cell having the plasmid of claim 8 transformed therein.

12. A single-stranded DNA enzyme comprising a 15 nucleotide catalytic domain flanked by random RNA target-binding domains of between about 7 and about 10 nucleotides each.

13. The single-stranded DNA enzyme of claim 12 wherein said catalytic domain comprises the sequence 5'-N₁-GGCTAGCTACAACGA-N₂-3' [Seq. ID No. 7], where N₁ and N₂ represent any sequence of nucleotides ranging in size from about seven to about ten nucleotides that target a specific RNA.

14. A plasmid having a sequence coding for the DNA enzyme of claim 12 contained therein.

15. A cell having the plasmid of claim 14 transformed therein.

16. The ODN expression plasmid AS080103.

17. A method of treatment of sepsis in an animal patient comprising the steps of contacting the causative agent of sepsis with an ODN comprising a sequence targeted to a specific gene of the causative agent for altering the expression of the specific gene to inhibit growth of the causative agent, kill the causative agent, or inhibit the synthesis or secretion of toxin by the causative agent.

18. A DNA, RNA, or PNA oligonucleotide for treatment of sepsis having one or more of the following nucleotide sequences:

5'(CTT TCA ACA GTT TTG ATG ACC TTT GCT GAC CAT ACA
ATT GCG ATA TCG TGG GGA GTG AGA G)3';

5'(CTC ATA CTC T)3'; or

5'(GTT TCG AAG GCT AGC TAC AAC GAT CAT CCA G)3'.

19. A cell having one or more of the sequences of claim 18 transformed therein.

20. An oligonucleotide having the sequence

5'-CTTTCAACAGTTTTGATGACCTTTGCTGACCATAACAATTGC-
GATATCGTGGGGAGTGAGAG-3' [Seq. ID No. 13].

Or one of the following sequences homologous thereto:

5'-CCTTTGCTGACCATAC-3'	[Seq. ID No. 14]
5'-GACCTTTGCTGACCA-3'	[Seq. ID No. 15]
5'-ACAGTTTTGATGAC-3'	[Seq. ID No. 16]
5'-ACAATTGCGATAT-3'	[Seq. ID No. 17]
5'-GACCTTTGCTGAC-3'	[Seq. ID No. 18]
5'-TCAACAGTTTTGATGAC-3'	[Seq. ID No. 19]
5'-ATGACCTTTGCTG-3'	[Seq. ID No. 20]
5'-CAGTTTTGATGA-3'	[Seq. ID No. 21]
5'-ACCTTTGCTGAC-3'	[Seq. ID No. 22]
5'-TTGCTGACCATA-3'	[Seq. ID No. 23]
5'-TGACCTTTGCTG-3'	[Seq. ID No. 24]
5'-GTTTTGATGACC-3'	[Seq. ID No. 25]
5'-GCGATATCGTGG-3'	[Seq. ID No. 26]
5'-TTGATGACCTTT-3'	[Seq. ID No. 27]
5'-TGGGGAGTGAG-3'	[Seq. ID No. 28]
5'-TTGCTGACCAT-3'	[Seq. ID No. 29]
5'-TTTTGATGACC-3'	[Seq. ID No. 30]
5'-TGATGACCTTT-3'	[Seq. ID No. 31].

21. A plasmid having a sequence coding for one or more of the oligonucleotides of claim 20 contained therein.

22. A cell having the plasmid of claim 21 transformed therein.

23. A single-stranded DNA enzyme comprising the nucleotide sequence 5'-N₁-GGCTAGCTACAACGA-N₂-3' [Seq. ID No. 7], and sequences homologous thereto, where N₁ and N₂ represent any sequence of nucleotides ranging in size from about seven to about ten nucleotides that are adapted for targeting a specific RNA.

24. The single-stranded DNA enzyme of claim 23 wherein N_1 and N_2 are comprised of a sequence specific for a sequence comprising a portion of the mRNA transcript of the bacterial FtsZ gene, and/or a sequence homologous thereto.

25. A plasmid having a sequence coding for the single-stranded DNA enzyme of claim 23 contained therein.

26. A peptide-PNA conjugate comprising the sequence KFFKFFKFFK CTC ATA CTC T [Seq. ID No. 34].

27. An oligonucleotide capable of binding to an mRNA transcribed from a cell growth, replication or toxin production or secretion gene of a bacterial or fungal pathogen, wherein the binding alters the activity of the gene.

28. An oligonucleotide according to Claim 27 wherein the oligonucleotide is selected from:

5'-CTTTCAACAGTTTTGATGACCTTTGCTGACCATAACAATTGC-
GATATCGTGGGGAGTGAGAG-3' [Seq. ID No. 13]

5'-CCTTTGCTGACCATAC-3' [Seq. ID No. 14]

5'-GACCTTTGCTGACCA-3' [Seq. ID No. 15]

5'-ACAGTTTTGATGAC-3' [Seq. ID No. 16]

5'-ACAATTGCGATAT-3' [Seq. ID No. 17]

5'-GACCTTTGCTGAC-3' [Seq. ID No. 18]

5'-TCAACAGTTTTGATGAC-3' [Seq. ID No. 19]

5'-ATGACCTTTGCTG-3' [Seq. ID No. 20]

5'-CAGTTTTGATGA-3' [Seq. ID No. 21]

5'-ACCTTTGCTGAC-3' [Seq. ID No. 22]

5'-TTGCTGACCATA-3' [Seq. ID No. 23]

5'-TGACCTTTGCTG-3' [Seq. ID No. 24]

5'-GTTTTGATGACC-3' [Seq. ID No. 25]

5'-GCGATATCGTGG-3' [Seq. ID No. 26]

5'-TTGATGACCTTT-3' [Seq. ID No. 27]

5'-TGGGGAGTGAG-3' [Seq. ID No. 28]

5'-TTGCTGACCAT-3' [Seq. ID No. 29]

5'-TTTTGATGACC-3' [Seq. ID No. 30]

5'-TGATGACCTTT-3' [Seq. ID No. 31]

29. An oligonucleotide according to Claim 27 or 28 wherein the binding prevents translation of the mRNA and the alteration is a reduction in the gene product.

30. An oligonucleotide according to any one of Claims 27-29 wherein the oligonucleotide is selected from single stranded DNA (ssDNA), RNA, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioates or phosphorothioates morpholino oligo (PMO).

31. An oligonucleotide according to any one of Claims 27-30 wherein the pathogen is a sepsis causative agent.

32. An oligonucleotide according to any one of Claims 27-31 wherein the pathogen is selected from Gram-negative bacteria *Bacteroides*, *Fusobacterium*, *Escherichia*, *Klebsiella*, *Salmonella*, *Shigella*, *Proteus*, *Pseudomonas*, *Vibrio*, *Legionella*, *Haemophilus*, *Bordetella*, *Brucella*, *Campylobacter*, *Neisseria*, *Branhamella*, Gram-positive bacteria such as *Streptococcus*, *Staphylococcus*, *Peptococcus*, *Bacillus*, *Listeria*, *Clostridium*, *Propionibacteria*, organisms that stain poorly or not at all with Gram's stain *Mycobacteria*, *Treponema*, *Leptospira*, *Borrelia*, *Mycoplasma*, *Chlamydia*, *Rickettsia* and *Coxiella*, or fungi *Candida*, *Aspergillosis*, *Blastomycosis*, *Coccidioidomycosis*, *Cryptococcosis*, *Histoplasmosis*, *Paracoccidiomycosis*, *Sporotrichosis*, *Zygomycosis*.

33. An oligonucleotide according to any one of Claims 27-32 wherein the gene is involved in one of cell division, cell wall synthesis, protein synthesis (translation), nucleic acid synthesis, fatty acid metabolism and gene regulation.

34. An oligonucleotide according to any one of Claims 27-33 wherein the mRNA has been transcribed from a gene selected from the bacterial genes *FtsZ*, *MurB*, *acpP*, 16s rRNA, PBPs, DNAA, DNAC, *pcrA*, *rpoB*, *rpoA*, *rpoC*, *rpsC*, *rpsD*, *rpsF*, *rpsI*, *rpsJ*, *rpsM*, *rpsR*, *FabK*, *FabH*, *rplB*, *rplC*, *rplJ*, *rplK*, *rplM*, *rplN*, *rplO*, *rplP*, *rplR*, *rplT*, *rplV*, *rplX*, *rpmA*, *rpmL*, *valS*, *serS*, *proS*, *cysS*, *alaS*, *pheS*, *sporC*, *tsf*, *tufA*, *fus*, *secA*, *secV*, *pyrC*, *btuE*, *CaiB*, *ydgD*, *ygcQ*, *ftsH*, *ppiB*, *yihl*, *zntA*, *yicI*, *fluA*, *rplD*, *ilvB*, *lepB*, *aroK*, *mfd*, *rlpA*, *accA*, *pgpA*, or the fungal genes *ERG1*,

ERG2, ERG3, ERG4, ERG5, ERG6, ERG7, ERG11, ERG24, ERG25, ERGX, ERGY, CHS1, CHS2, CHS3, CWP1, CWP2, KRE1, KRE2, KRE5, KRE11, TIP1, GFA1.

35. An oligonucleotide nucleotide according to any one of Claims 27-34 wherein the oligonucleotide functions as an antisense molecule.

36. An oligonucleotide according to any one of Claims 27-34 wherein the oligonucleotide functions as a DNA enzyme.

37. An oligonucleotide according to Claim 36 wherein the DNA enzyme is a 10-23 DNA enzyme.

38. An oligonucleotide according to Claim 37 wherein the DNA enzyme takes the form

5'-N₁-GGCTAGCTACAACGA-N₂-3' [Seq. ID No. 7]

where N₁ and N₂ represent any sequence of nucleotides that target a specific RNA ranging in size from 3 to 25 nucleotides, and preferably seven to ten nucleotides.

39. An oligonucleotide according to Claim 37 wherein the DNA enzyme is

5'-GTTTCGAAGGCTAGCTACAACGATCATCCAG-3' [Seq. ID No. 6]

40. An oligonucleotide according to Claim 39 wherein the DNA enzyme binds FtsZ mRNA.

41. A conjugate comprising an oligonucleotide according to any one of Claims 27 to 41 and a peptide.

42. A conjugate according to Claim 41 wherein the peptide is KFFKFFKFFK or homologues and derivatives thereof.

43. A vector comprising an oligonucleotide according to any one of Claims 27 to 41.

44. A vector according to Claim 43 wherein the vector is an expression vector, preferably an inducible expression vector.

45. A host cell transformed with a vector according to any one of Claims 43 to 44.

46. A host cell according to Claim 45 wherein the cell is a bacterial or fungal pathogen, preferably a sepsis causative agent.

47. An oligonucleotide according to any one of Claims 27 to 40, a conjugate according to Claim 41 or 42, or a vector according to Claim 43 or 44, for use in treatment.

48. An oligonucleotide according to Claim 47 wherein the treatment is treatment of a bacterial or fungal pathogenic condition and preferably sepsis.

49. Use of an oligonucleotide according to any one of Claims 27 to 40 in the manufacture of a medicament for the treatment of a bacterial or fungal pathogenic condition

50. Use according to Claim 49 wherein the condition is caused by Bacteroides, Fusobacterium, Escherichia, Klebsiella, Salmonella, Shigella, Proteus, Pseudomonas, Vibrio, Legionella, Haemophilus, Bordetella, Brucella, Campylobacter, Neisseria, Branhamella, Streptococcus, Staphylococcus, Peptococcus, Bacillus, Listeria, Clostridium, Propionibacteria, Mycobacteria, Treponema, Leptospira, Borrelia, Mycoplasma, Chlamydia, Rickettsia and Coxiella, or Candida, Aspergillosis, Blastomycosis, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Paracoccidiomycosis, Sporotrichosis, Zygomycosis.

51. Use according to Claim 49 or 50 wherein the condition is sepsis.

52. A kit comprising:

(a) an oligonucleotide according to any one of Claims 27 to 40;

and

(b) a pharmaceutically acceptable excipient

for use in treating a bacterial or fungal pathological condition.

53. A kit according to Claim 52 wherein the condition is sepsis.

54. A kit according to Claim 52 to 53 wherein the pharmaceutically acceptable excipient is selected from a peptide, preferably KFFKFFKFFK, and a vector.

55. A library comprising at least one bacterial strain transformed with an inducible expression vector comprising a test oligonucleotide, wherein the bacterial strain is capable of causing a pathological condition.

56. A library according to Claim 55 wherein the pathological condition is sepsis.

57. A library according to Claim 55 or 56 wherein the bacterial strain is selected from Gram-negative bacteria *Bacteroides*, *Fusobacterium*, *Escherichia*, *Klebsiella*, *Salmonella*, *Shigella*, *Proteus*, *Pseudomonas*, *Vibrio*, *Legionella*, *Haemophilus*, *Bordetella*, *Brucella*, *Campylobacter*, *Neisseria*, *Branhamella*; Gram-positive bacteria *Streptococcus*, *Staphylococcus*, *Peptococcus*, *Bacillus*, *Listeria*, *Clostridium* and *Propionebacteria*.

58. A library according to any one of Claims 55 to 57 wherein the bacterial strain is *E. coli*, preferably DH5 α Pro cells.

59. A library according to any one of Claims 55 to 58 wherein the test oligonucleotide is at least 10, preferably 20, more preferably 30, still more preferably 40, even more preferably 50 and still even more preferably 60 bases long.

60. A library according to any one of Claims 55 to 59 wherein the inducible expression vector is modulated by tetracycline and preferably the vector is pssXGb.

61. A method for identifying an oligonucleotide for use in the treatment of a bacterial or fungal pathological condition comprising:

- (a) providing a library according to any one of Claims 55 to 60;
- (b) providing at least two samples of the at least one bacterial strain, under conditions supporting bacterial growth, wherein at least one sample is contacted with the inducer and at least one sample is not contacted with the inducer; and
- (c) selecting a bacterial strain capable of growing only in the absence of the inducer and isolating the test oligonucleotide.

62. A method according to Claim 61 wherein the condition is sepsis.

63. A method according to Claim 61 or 62 further comprising step (d) to be performed after step (c) comprising:

- (d) analysing the isolated test oligonucleotide to identify a target bacterial gene sequence.

64. A method according to any one of Claims 61 to 63 further comprising step (e) to be performed after step (c) or (d) comprising:

- (e) use of the isolated test oligonucleotide in a treatment for sepsis.

65. A method according to any one of Claims 61 to 64 wherein the bacterial strain is selected from *Bacteroides*, *Fusobacterium*, *Escherichia*, *Klebsiella*,

Salmonella, Shigella, Proteus, Pseudomonas, Vibrio, Legionella, Haemophilus, Bordetella, Brucella, Campylobacter, Neisseria, Branhamella; Streptococcus, Staphylococcus, Peptococcus, Bacillus, Listeria, Clostridium, Propionebacteria.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7



aTc (ng/ml)

Figure 8B




Figure 8A





Figure 9




Figure 10A





Figure 10B



Figure 11






FIG. 12 Mouse survival after infection

Serum IL-6




FIG. 13 Change in mouse serum IL-6 after infection





FIG. 14 Treatment time

AS080103

pssxGb



Fig. 15 Inhibition of bacterial growth by ODN expression plasmid



F76.16